Literature DB >> 22504408

Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study.

Cyrille Touzeau1, Katia Gagne, Véronique Sébille, Patricia Herry, Patrice Chevallier, Gilles Folléa, Anne Devys, Philippe Moreau, Mohamad Mohty, Anne Cesbron Gautier.   

Abstract

The impact of HLA-DPB1 mismatches after unrelated hematopoietic stem cell transplantation (HSCT) remains controversial. We retrospectively analyzed the impact of permissive/non-permissive HLA-DPB1 mismatches on the outcome of 141 patients who underwent 10/10 HLA allelic-matched unrelated HSCT. Each pair was classified according to the 3 (TCE3) and 4-group (TCE4) algorithm based on DPB1 alleles immunogenicity. Outcome analysis revealed that TCE3 and TCE4 non-permissive HLA-DPB1 disparities were not associated with worsened overall survival, relapse risk neither risk of acute GvHD. Overall, this single center retrospective study does not confirm the adverse prognostic of non-permissive HLA-DPB1 mismatches.
Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22504408     DOI： 10.1016/j.humimm.2012.03.013

Source DB:  PubMed          Journal:  Hum Immunol        ISSN： 0198-8859            Impact factor:   2.850


  2 in total

1.  Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study.

Authors:  K Gagne; P Loiseau; V Dubois; F Dufossé; P Perrier; A Dormoy; I Jollet; V Renac; D Masson; C Picard; X Lafarge; D Hanau; F Quainon; F Delbos; B Coeffic; Léna Absi; J-F Eliaou; V Moalic; M Fort; M de Matteis; I Theodorou; F Hau; A Batho; B Pedron; S Caillat-Zucman; E Marry; N Raus; I Yakoub-Agha; A Cesbron
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors.

Authors:  C Burt; A Parker; G McQuaker; M Copland; C Brierley; A-M Little; A Clark
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.